Rotigotine CDS (constant delivery system) is a transdermal formulation of the dopamine agonist N-0923 (SPM-962), an aminotetralin dopamine D2 agonist. It was originally developed by Discovery Therapeutics (DTI), which became Aderis Pharmaceuticals in January 2002.